Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Progressive Corp — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Progressive Corp trades at $217.43 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 10.1× Halozyme Therapeutics Inc. Common Stock's market cap, and Progressive Corp pays a 0.18% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Progressive Corp for 81 Days on average.
| HALO | PGR | |
|---|---|---|
Market Cap | $12.58B | $126.95B |
Volume | 2,179,278 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $115.22 | $240.40 |
52-Week Low | $61.63 | $190.40 |
Typical Hold Time | 1 Days | 81 Days |
Enterprise Value | $14.49B | $135.16B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PGR trades at $218.73, up 2.15% on the day, with a bullish technical signal and strong fundamentals. Revenue has grown from $49.6B in 2022 to $87.6B in 2025, with net income reaching $11.3B. The stock is supported by a consensus price target of $222.23 and positive analyst sentiment, though RSI levels suggest some near-term overbought conditions.
The outlook for PGR is positive, driven by consistent earnings beats and robust profitability metrics like a 34.94% ROE. Risks include competitive pressures in personal auto insurance and potential market volatility. The stock offers a solid investment opportunity with upside to the price target, but investors should monitor underwriting discipline amid industry competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
